Kenneth N Olivier1, David E Griffith2, Gina Eagle3, John P McGinnis3, Liza Micioni3, Keith Liu3, Charles L Daley4, Kevin L Winthrop5, Stephen Ruoss6, Doreen J Addrizzo-Harris7, Patrick A Flume8, Daniel Dorgan9, Matthias Salathe10, Barbara A Brown-Elliott2, Renu Gupta3,11, Richard J Wallace2. 1. 1 National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. 2. 2 The University of Texas Health Science Center at Tyler, Tyler, Texas. 3. 3 Insmed Incorporated, Bridgewater, New Jersey. 4. 4 National Jewish Health, Denver, Colorado. 5. 5 Oregon Health & Science University, Portland, Oregon. 6. 6 Stanford University School of Medicine, Stanford, California. 7. 7 New York University School of Medicine, New York, New York. 8. 8 Medical University of South Carolina, Charleston, South Carolina. 9. 9 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 10. 10 Leonard M. Miller School of Medicine, University of Miami, Miami, Florida; and. 11. 11 Global Biopharma, Moorestown, New Jersey.
Abstract
RATIONALE: Lengthy, multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease. OBJECTIVES: In this phase II study, we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-refractory pulmonary nontuberculous mycobacterial (Mycobacterium avium complex [MAC] or Mycobacterium abscessus) disease. METHODS: During the double-blind phase, patients were randomly assigned to LAI (590 mg) or placebo once daily added to their multidrug regimen for 84 days. Both groups could receive open-label LAI for 84 additional days. The primary endpoint was change from baseline to Day 84 on a semiquantitative mycobacterial growth scale. Other endpoints included sputum conversion, 6-minute-walk distance, and adverse events. MEASUREMENTS AND MAIN RESULTS: The modified intention-to-treat population included 89 (LAI = 44; placebo = 45) patients. The average age of the sample was 59 years; 88% were female; 92% were white; and 80 and 59 patients completed study drug dosing during the double-blind and open-label phases, respectively. The primary endpoint was not achieved (P = 0.072); however, a greater proportion of the LAI group demonstrated at least one negative sputum culture (14 [32%] of 44 vs. 4 [9%] of 45; P = 0.006) and improvement in 6-minute-walk test (+20.6 m vs. -25.0 m; P = 0.017) at Day 84. A treatment effect was seen predominantly in patients without cystic fibrosis with MAC and was sustained 1 year after LAI. Most adverse events were respiratory, and in some patients it led to drug discontinuation. CONCLUSIONS: Although the primary endpoint was not reached, LAI added to a multidrug regimen produced improvements in sputum conversion and 6-minute-walk distance versus placebo with limited systemic toxicity in patients with refractory MAC lung disease. Further research in this area is needed. Clinical trial registered with www.clinicaltrials.gov (NCT01315236).
RCT Entities:
RATIONALE: Lengthy, multidrug, toxic, and low-efficacy regimens limit management of pulmonary nontuberculous mycobacterial disease. OBJECTIVES: In this phase II study, we investigated the efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-refractory pulmonary nontuberculous mycobacterial (Mycobacterium avium complex [MAC] or Mycobacterium abscessus) disease. METHODS: During the double-blind phase, patients were randomly assigned to LAI (590 mg) or placebo once daily added to their multidrug regimen for 84 days. Both groups could receive open-label LAI for 84 additional days. The primary endpoint was change from baseline to Day 84 on a semiquantitative mycobacterial growth scale. Other endpoints included sputum conversion, 6-minute-walk distance, and adverse events. MEASUREMENTS AND MAIN RESULTS: The modified intention-to-treat population included 89 (LAI = 44; placebo = 45) patients. The average age of the sample was 59 years; 88% were female; 92% were white; and 80 and 59 patients completed study drug dosing during the double-blind and open-label phases, respectively. The primary endpoint was not achieved (P = 0.072); however, a greater proportion of the LAI group demonstrated at least one negative sputum culture (14 [32%] of 44 vs. 4 [9%] of 45; P = 0.006) and improvement in 6-minute-walk test (+20.6 m vs. -25.0 m; P = 0.017) at Day 84. A treatment effect was seen predominantly in patients without cystic fibrosis with MAC and was sustained 1 year after LAI. Most adverse events were respiratory, and in some patients it led to drug discontinuation. CONCLUSIONS: Although the primary endpoint was not reached, LAI added to a multidrug regimen produced improvements in sputum conversion and 6-minute-walk distance versus placebo with limited systemic toxicity in patients with refractory MAClung disease. Further research in this area is needed. Clinical trial registered with www.clinicaltrials.gov (NCT01315236).
Authors: David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop Journal: Am J Respir Crit Care Med Date: 2007-02-15 Impact factor: 21.405
Authors: Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Steven M Holland; D Rebecca Prevots Journal: Am J Respir Crit Care Med Date: 2012-02-03 Impact factor: 21.405
Authors: David E Griffith; Jennifer Adjemian; Barbara A Brown-Elliott; Julie V Philley; D Rebecca Prevots; Christopher Gaston; Kenneth N Olivier; Richard J Wallace Journal: Am J Respir Crit Care Med Date: 2015-09-15 Impact factor: 21.405
Authors: Kenneth N Olivier; Pamela A Shaw; Tanya S Glaser; Darshana Bhattacharyya; Michelle Fleshner; Carmen C Brewer; Christopher K Zalewski; Les R Folio; Jenifer R Siegelman; Shamira Shallom; In Kwon Park; Elizabeth P Sampaio; Adrian M Zelazny; Steven M Holland; D Rebecca Prevots Journal: Ann Am Thorac Soc Date: 2014-01
Authors: J van Ingen; S A Bendien; W C M de Lange; W Hoefsloot; P N R Dekhuijzen; M J Boeree; D van Soolingen Journal: Thorax Date: 2009-02-12 Impact factor: 9.139
Authors: J P Clancy; L Dupont; M W Konstan; J Billings; S Fustik; C H Goss; J Lymp; P Minic; A L Quittner; R C Rubenstein; K R Young; L Saiman; J L Burns; J R W Govan; B Ramsey; R Gupta Journal: Thorax Date: 2013-06-08 Impact factor: 9.139